$6.13
0.223.72%
At close: Apr 16, 5:00 PM EST
$5.31
-0.60-10.15%
Pre-Market: 7:31 AM EST
Harvard Bioscience Inc Analyst Ratings
HBIONASDAQ
Harvard Bioscience Analyst Ratings and Price Targets | NASDAQ:HBIO | Benzinga
Harvard Bioscience Inc has a consensus price target of $4.5 based on the ratings of 3 analysts. The high is $6 issued by Benchmark on March 16, 2026. The low is $3 issued by Benchmark on May 13, 2025. The 3 most-recent analyst ratings were released by Benchmark on March 16, 2026, March 13, 2026, and September 10, 2025, respectively. With an average price target of $2.87 between Benchmark, there's an implied -46.01% downside for Harvard Bioscience Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Benchmark
1calculated from analyst ratings
Analyst Ratings for Harvard Bioscience
Loading calendar...
FAQ
What is the target price for Harvard Bioscience (HBIO) stock?
The latest price target for Harvard Bioscience (NASDAQ:HBIO) was reported by Benchmark on March 16, 2026. The analyst firm set a price target for $6.00 expecting HBIO to rise to within 12 months (a possible 12.99% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Harvard Bioscience (HBIO)?
The latest analyst rating for Harvard Bioscience (NASDAQ:HBIO) was provided by Benchmark, and Harvard Bioscience maintained their speculative buy rating.
When was the last upgrade for Harvard Bioscience (HBIO)?
There is no last upgrade for Harvard Bioscience
When was the last downgrade for Harvard Bioscience (HBIO)?
The last downgrade for Harvard Bioscience Inc happened on April 9, 2025 when Keybanc changed their price target from N/A to N/A for Harvard Bioscience Inc.
When is the next analyst rating going to be posted or updated for Harvard Bioscience (HBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harvard Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harvard Bioscience was filed on March 16, 2026 so you should expect the next rating to be made available sometime around March 16, 2027.
Is the Analyst Rating Harvard Bioscience (HBIO) correct?
While ratings are subjective and will change, the latest Harvard Bioscience (HBIO) rating was a maintained with a price target of $0.60 to $6.00. The current price Harvard Bioscience (HBIO) is trading at is $5.31, which is within the analyst’s predicted range.
